Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.37 |
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4219033 | 0.82 | KDM4E (0.46) | CHEK1KDM4EPOLBRPS6KB1RAB9A | |
| SCHEMBL4703508 | 0.82 | KDM4E (0.46) | CHEK1KDM4EPOLBMEN1KMT2A | |
| SCHEMBL4210048 | 0.79 | CHEK1 (0.44) | CHEK1KDM4EPOLBPROKR1RAB9A | |
| SCHEMBL4213189 | 0.79 | DYRK1A (0.46) | KDM4EPOLBMEN1KMT2A | |
| SCHEMBL4223869 | 0.78 | CHEK1 (0.53) | CHEK1KDM4EPOLB | |
| SCHEMBL4212719 | 0.77 | CHEK1 (0.78) | CHEK1 | |
| SCHEMBL4210074 | 0.77 | CHEK1 (0.54) | CHEK1KDM4EPOLB | |
| SCHEMBL4208178 | 0.77 | KDM4E (0.51) | CHEK1KDM4EPOLBRAB9ASMN1; SMN2 | |
| SCHEMBL5001102 | 0.77 | USP30 (0.43) | CHEK1KDM4EPOLBMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL4218765 | 0.76 | CHEK1 (0.77) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054396-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| EP-1660474-B1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-10-29 | — | — | EP | claimed |
| US-7423061-B2 | Substitute thiophenes and uses thereof | ASTRAZENECA AB (SE) | 2008-09-09 | — | — | US | claimed |
| JP-2007502308-A | — | — | 2007-02-08 | — | — | JP | claimed |
| US-20060281666-A1 | Substitute thiophenes and uses therof | ASTRAZENECA AB (SE) | 2006-12-14 | — | — | US | claimed |
| EP-1660474-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | claimed |
| WO-2005016909-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | WO | claimed |
| US-20090054396-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| US-20090054396-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| US-20090054396-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-1660474-B1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-10-29 | — | — | EP | disclosed |
| US-7423061-B2 | Substitute thiophenes and uses thereof | ASTRAZENECA AB (SE) | 2008-09-09 | — | — | US | disclosed |
| US-7423061-B2 | Substitute thiophenes and uses thereof | ASTRAZENECA AB (SE) | 2008-09-09 | — | — | US | disclosed |
| US-7423061-B2 | Substitute thiophenes and uses thereof | ASTRAZENECA AB (SE) | 2008-09-09 | — | — | US | disclosed |
| US-20060281666-A1 | Substitute thiophenes and uses therof | ASTRAZENECA AB (SE) | 2006-12-14 | — | — | US | disclosed |
| EP-1660474-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005016909-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054396-A1 | SUBSTITUTED THIOPHENES AND USES THEREOF | TPMT, ABCG2, TYMP | CHEK1 297/4885KDM4E 1951/4885POLB 1837/4885 |
| US-20060281666-A1 | Substitute thiophenes and uses therof | TYMP, TPMT, MGMT | CHEK1 602/4885KDM4E 3570/4885POLB 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.